Phase II study of Gemcitabine and Cisplatin Regimen in Advanced Non-Small Cell Lung Cancer (NSCLC).
,
Abstract
Background: Cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (NSCLC). Many novel drugs, including gemcitabine, vinorelbine, paclitaxel and docetaxel have been used in combination with cisplatin in this setting. Of these drugs, gemcitabine is reported to have a high response rate and acceptable toxicity. The aim of this study was to evaluate the efficacy and safety of gemcitabine & cisplatin combination.
Methods: Twenty-three patients with NSCLC, who met inclusion criteria, were enrolled from January 2001 till September 2003. All of them were confirmed by histology and were in advanced stages, i.e. stage IIIB or stage IV. Cisplatin with a dose of 70mg/m2 was given every 21 days, in combination with gemcitabine at a dose of 1250mg/m2 administered on days 1and 8 of a 21-day cycle.
Results: of the 23 patients, 1 showed complete remission, 5 achieved partial remission, 7 had stable disease and 2 patients showed progressive disease, while 8 patients were not evaluable for response. The overall response in 15 evaluable patients was 40% (95% CI), median survival was 13.5 months (95% CI, 3.5-27.4 months), and median progression free survival (PFS)was 11 months (95% CI, 1.04-20.9 months).
Hematological toxicities included WHO grade 3, 4 anemia, neutropenia and thrombocytopenia 10%, 7% and 2% respectively. Non-Hematological toxicities included nausea/vomiting WHO grade 1,2 & peripheral neuropathy WHO grade 1,2. Skin rashes were mild.Six patients developed grade 2 toxicity. Renal impairment was mild. One case developed Acute Respiratory distress syndrome (ARDS) after first dose of chemotherapy, another case developed transient acute psychosis under therapy.
Conclusions: The regimen of combined gemcitabine with cisplatin is safe and effective and well toler¬ated in patients. Some rare but important toxicity such as ARDS may occur occasionally. In this com¬bination, a lower dose of cisplatin seems to have an efficacy similar to that of in previous reports.
Ries LG, Pollack ES, Young J Jr. Cancer Patient Survival: Surveilance, Epidemiology, and End Results Program, 1973-79. J Natl cancer Inst 1983; 70: 693-707.
Murphy GP, Lawrence WJ, Lenhard REJ, eds. American cancer society textbook of clinical oncology, 2nd edn. Atlanta: American Cancer Society, 1995.
Ganz P, figlin R, Haskell C, et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer 1989; 63: 1271- 1278.
Quoix et al IS chemotherapy with cisplatin useful in non-small cell bronchial cancer at staging IU? Results of a randomized study. Bull cancer 1991; 78: 341-346.
Non-Small cell lung cancer collaborative Group. Chemotherapy in non-small cell lung cancer: a meta- analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899- 909.
Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2, 2-difloorodeoxycytidine on DNA synthesis. Cancer Ros 1991; 51: 611107.
Abratt RP, Bezwoda WR, Falkson C. Efficacy and Safety profile of gemcitabine in non-small cell lung can- cer: a phase II study. J Clin. Oncol. 1994; 12: 1535-40.
Anderson H, Lund B, Bach F. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin. Oncol. 1994; 12: 1821-6
Gatzemeier U, Shepherd FA, Le Chevalier T. Activ- ity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur. J. Cancer 1996; 32A: 243-8.
Fossella FV, Lippman SM, Tarasaoff P. Phase I/II study of gemcitabine, an active agent for advanced non- small cell lung cancer (NSCLC). Proc Am. Soc. Clin. Oncol. 1995; 14 (abstract 1144): 371.
Peters GJ, Ruiz van Haperen VWT, Bergman AM. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol 1995; 2(Suppl 11): 72-9.
Tsai C-M, Chang K-T, Chen J-Y. Cytotoxic effects of gemcitabine-containing regimens against human non- small cell lung cancer cell lines which express different levels of P185neul.
Loehere PJ, Einhorn LH. Cisplatin. Ann Intern Med 1984; 100: 704-13.
Zamble DM, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sc.i 1995; 20: 435-9.
Shepherd FA, Cormier Y, Burkes R, Evans WK, Goss G, Klimo P, et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin. Oncol. 1997; 24 (3 Suppl. 8): S8-27-S8-30.
Lippe P, Tummarello D, Monterubbianesi MC, Silva RR, Giuliodori L, Mari D, et al. Weekly gemcitabine & cisplatin in advanced non-small-cell lung cancer: a phase II study. Am. Oncol. 1999; 10:217-21.
Steward WP, Dunlop DJ, Dabouis G. Phase I/II study of gemcitabine and cisplatin in the treatment of ad- vanced non-small lung cancer: preliminary results. Semin. Oncol. 1996; 23 (Suppl 10): 43-7.
Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer: J Clin. Oncol. 1997; 15: 744-9.
Einhorn LH. Phase II trial of gemcitabine plus cis- platin in non-small cell lung cancer: a Hoosier Oncology Group study. Semin. Oncol. 1997; 24(Suppl 8): 24-6.
Crino L, Scagliotti G, Marangolo M. Cisplatin- gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin. Oncol. 1997; 15: 297-303.
Abratt RP, Sandler A, Crino L, Steward WP, Shep- herd FA, Green MR, et al. Combined cisplatin and gem- citabine for non-small cell cancer: influence of schedul- ing on toxicity and drug delivery. Semin. Oncol. 1998; 25(4 Suppl 9): 35-43.
| Files | ||
| Issue | Vol 2, No 2 (2005) | |
| Section | Articles | |
| Keywords | ||
| Non small cell lung cancer (NSCLC) Gemcitabine | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
